The company is a large state-owned listed pharmaceutical company, mainly engaged in R&D, production, sales of pharmaceutical products and related health services. It was listed on the Shenzhen Stock Exchange on March 9, 2000 (stock code: 000999) and officially joined China Resources Group in 2008. China Resources 39's vision is to become China's “leader in the popular medical and health industry”, innovatively apply traditional Chinese and Western medicine science and technology, focus on innovative research and development and intelligent manufacturing of high-quality medical and health products, serve every member of the Chinese family, and is committed to becoming the number one medical and health brand in China. The company's products include 999 cold medicine, 999 dermatitis tablets, 39 stomach tablets, 999 pediatric colds, gas stagnation and stomach pain granules, Tianhe bone patch; it contains injections, Ace of Liqin softgels, Huaxanthin tablets and injections, Prehematogen capsules, Jinfukang oral solution, Yin Jihuang oral liquid; xintelin, azithromycin enteric capsules, erythromycin enteric capsules, etc., antibiotic products such as erythromycin enteric capsules, erythromycin enteric capsules, etc. Loratadine and other products. Corporate honors: The company has been named “Top 100 Valuable” and “Top 100 Golden Bull” companies listed on China's main board many times. Up to now, China Resources 39 has been included in the SZSE Component Index, China Securities 500, MSCI Emerging Markets Index, and FTSerRussell (FTSerRussell).